TG Therapeutics (NASDAQ:TGTX) Shares Down 2.9% - Time to Sell?

Shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Get Free Report) traded down 2.9% on Monday . The stock traded as low as $29.01 and last traded at $29.19. 195,725 shares traded hands during trading, a decline of 87% from the average session volume of 1,519,561 shares. The stock had previously closed at $30.05.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the company. JPMorgan Chase & Co. upped their price target on TG Therapeutics from $30.00 to $43.00 and gave the stock an "overweight" rating in a research report on Monday, November 25th. StockNews.com downgraded shares of TG Therapeutics from a "hold" rating to a "sell" rating in a research report on Sunday, December 22nd. TD Cowen assumed coverage on shares of TG Therapeutics in a research report on Tuesday, October 29th. They set a "buy" rating and a $50.00 price target on the stock. HC Wainwright raised their price objective on TG Therapeutics from $49.00 to $55.00 and gave the company a "buy" rating in a report on Tuesday, November 5th. Finally, The Goldman Sachs Group lifted their target price on TG Therapeutics from $20.00 to $22.00 and gave the company a "neutral" rating in a research report on Tuesday, November 5th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $40.67.

TG Therapeutics Price Performance

The company's 50-day simple moving average is $31.26 and its 200-day simple moving average is $25.16. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91. The stock has a market capitalization of $4.36 billion, a price-to-earnings ratio of -279.97 and a beta of 2.24.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last released its quarterly earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.01). The firm had revenue of $83.90 million during the quarter, compared to the consensus estimate of $81.68 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The business's revenue for the quarter was down 49.4% compared to the same quarter last year. During the same quarter last year, the firm earned $0.73 earnings per share. Research analysts forecast that TG Therapeutics, Inc. will post 0.17 earnings per share for the current fiscal year.

Insider Activity at TG Therapeutics

In other news, Director Sagar Lonial sold 5,000 shares of TG Therapeutics stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $30.44, for a total value of $152,200.00. Following the completion of the sale, the director now directly owns 100,195 shares in the company, valued at approximately $3,049,935.80. The trade was a 4.75 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 10.50% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On TG Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. GAMMA Investing LLC grew its holdings in shares of TG Therapeutics by 562.4% during the 4th quarter. GAMMA Investing LLC now owns 2,557 shares of the biopharmaceutical company's stock worth $77,000 after purchasing an additional 2,171 shares in the last quarter. JPMorgan Chase & Co. grew its stake in TG Therapeutics by 60.0% during the third quarter. JPMorgan Chase & Co. now owns 720,798 shares of the biopharmaceutical company's stock worth $16,859,000 after buying an additional 270,286 shares in the last quarter. Principal Financial Group Inc. increased its holdings in TG Therapeutics by 1,549.4% in the 3rd quarter. Principal Financial Group Inc. now owns 772,188 shares of the biopharmaceutical company's stock valued at $18,061,000 after buying an additional 725,371 shares during the period. Franklin Resources Inc. raised its position in shares of TG Therapeutics by 3.8% in the 3rd quarter. Franklin Resources Inc. now owns 128,985 shares of the biopharmaceutical company's stock valued at $2,945,000 after buying an additional 4,756 shares in the last quarter. Finally, Synovus Financial Corp bought a new stake in shares of TG Therapeutics during the 3rd quarter worth approximately $465,000. Institutional investors own 58.58% of the company's stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.